Back to discover
Drug

Henagliflozin

Late-stage clinical development
ClassSodium/glucose cotransporter 2 inhibitor
5
Active clinical trials
Sodium/glucose cotransporter 2
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Henagliflozin Delays the Progress of Diabetic Nephropathy Via Regulates Gut-Renal Axis

Clinical trial2024-12-31Primary completion · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Henagliflozin
RxNorm CUI
1904202
ChEMBL ID
CHEMBL4297431
UNII
21P2M98388
Primary mechanism
Sodium/glucose cotransporter 2 inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

INHIBITORSodium/glucose cotransporter 2 inhibitor

Clinical trials

13 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
13
registered trials across all phases
LATEST COMPLETION 2025
5
Active studies
5
Recruiting
13
Late-stage (III+)
3
Completed
5
Discontinued
PHASE DISTRIBUTIONn = 13
Phase 31Phase 47Phase N / A5

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials